胃炎Ⅰ号对大鼠胃癌前病变组织基质金属蛋白酶-7、9调控机制的研究
|
摘要
研究背景:
胃癌是消化系统常见的恶性肿瘤之一,位居全球肿瘤发病率和癌症病死率的第二位,严重威胁着人类的健康。然而其病因病机尚不明确,无法进行针对病因的一级预防,但胃粘膜的癌变往往经历较长的癌前病变阶段,呈现慢性浅表性胃炎一慢性萎缩性胃炎—肠上皮化生—不典型增生—癌变的趋势。其中,不典型增生和肠上皮化生被称为癌前病变。因此,针对癌前病变的二级预防是防治胃癌的关键。如果能在胃癌前病变阶段及早诊断,及早治疗,则能极大的降低胃癌的死亡率。中医药在防治胃癌前病变方面展示出独特的优势。胃炎Ⅰ号是导师刘友章教授根据中医脾胃为后天之本,气血生化之源的理论,结合临床,创制的纯中药复方。在临床应用中取得了很好的疗效。前期研究已初步证实了胃炎Ⅰ号对脾胃虚弱型慢性萎缩性(CAG)胃炎病人和CAG模型大鼠胃粘膜修复有很好的疗效,并有一定的抗肠上皮化生的作用。本课题拟研究胃炎Ⅰ号治疗胃癌前病变可能的作用机制。近年来许多研究证实胃癌中基质金属蛋白酶(MMPs)出现过度表达和活性提高。MMPs是内源性蛋白水解酶,它主要通过降解细胞外基质、调节细胞间黏附、以及促进新生血管形成等参与组织重构、细胞增殖、恶性细胞浸润、转移等。MMP-7、9是MMPs家族中重要成员,它们的过度表达或活性的提高与肿瘤的生长、浸润和转移等有密切关系。此外,一些研究已证明,MMP-7、9在癌前病变组织中的表达较慢性胃炎组织中的表达升高。那么,胃炎Ⅰ号方治疗胃癌前病变的机制是否与MMP-7、9有关?这将是本课题研究的重点。
研究目的:
本课题通过临床研究对胃炎Ⅰ号方临床疗效进行较为客观的评价,并使用分子生物学技术以及免疫组织化学技术等,观察大鼠胃组织中MMP-7、9蛋白的表达、酶的活性,以及MMP-7mRNA、MMP-9mRNA的表达,从而初步探索胃炎Ⅰ号治疗胃癌前病变可能的作用机制,为临床更好的使用该方提供理论依据。
研究方法:
1.动物实验:将84只大鼠,雌雄各半,按体重随机分为6组,模型组24只,空白组、胃炎Ⅰ号大、中、小剂量组及维酶素组各12只。造模期间,空白组给予正常饮食以及等体积生理盐水灌胃。其余各组给予以下处理措施:①50μg/mL N-甲基-N'-硝基-亚硝基胍(MNNG)溶液自由饮用,造模期间不再给予其他饮水;②盐酸雷尼替丁水溶液按每天0.03g/kg灌胃,每日1次;③饥饱失常:连续2d喂食,保证足量,1d停食。造模共20周。造模成功后,胃炎Ⅰ号大、中、小剂量组分别使用2.16g/(kg·d)、1.08g/(kg·d)、0.54g/(kg·d)的胃炎Ⅰ号水煎液灌胃。维酶素组用0.86g/(kg·d)的维酶素水溶液灌胃。空白组和模型组均用0.18g/(kg·d)的生理盐水灌胃。给药3个月。实验结束后观察大鼠一般情况,取胃组织做病理检查。使用免疫组化技术观察MMP-7、MMP-9蛋白的表达。使用明胶酶谱法观察MMP-7、MMP-9酶的活性。使用聚合酶链反应(PCR)技术观察MMP-7mRNA、MMP-9mRNA的表达。
2.临床观察:符合纳入标准的胃癌前病变患者30例,按就诊时间随机分为胃炎Ⅰ号治疗组和维酶素对照组,每组各15例。采用中医症候量表进行观察,比较两组治疗前后中医症状评分、两组患者的中医疗效,以及治疗后药物安全性观察。从而对胃炎Ⅰ号方治疗胃癌前病变的临床疗效做出客观的评价。
研究结果:
1.动物试验:病理结果显示大鼠胃粘膜腺体萎缩,伴有肠上皮化生和不典型增生,提示造模成功。经胃炎Ⅰ号和维酶素治疗后,上述病理改变减轻或消失。
大鼠胃组织MMP-7的表达:空白组与模型组比较有统计学意义(P=0.000)。大、中、小剂量组及维酶素组与模型组比较有统计学意义(P=0.000,P=0.000,P=0.005,P=0.032)。大、中、小剂量组之间无统计学意义,中剂量组与维酶素组之间有统计学意义(P=0.032)。大、小剂量组与维酶素组之间无统计学意义(P=0.093,P=0.466)。
大鼠胃组织MMP-9的表达:空白组与模型组比较有统计学意义(P=0.001)。大、中、小剂量组及维酶素组与模型组比较有统计学意义(P=0.002,P=0.000,P=0.002,P=0.012)。大、中、小剂量组及维酶素组之间无统计学意义。
大鼠胃组织MMP-7活性:χ~2=26.533,df=5,P=0.000,各组间差异有统计学意义。从平均秩次的变化趋势看模型组活性最高,空白组活性最低。中剂量组较大、小剂量组、维酶素组MMP-7活性低。
大鼠胃组织MMP-9活性:χ~2=24.386,df=5,P=0.000,各组间差异有统计学意义。从平均秩次的变化趋势看模型组MMP-9活性最高,空白组活性最低。中剂量组较大、小剂量组、维酶素组MMP-9活性低。
大鼠胃组织MMP-7mRNA表达:χ~2=11.730,df=5,P=0.039,各组间差异有统计学意义。从平均秩次的变化趋势看模型组MMP-9mRNA表达水平较空白组上调。胃炎Ⅰ号大、中、小剂量组和维酶素组较模型组表达水平下调。
大鼠胃组织MMP-9mRNA表达:χ~2=11.385,df=5,P=0.044,各组间差异有统计学意义。从平均秩次的变化趋势看模型组MMP-9mRNA表达水平较空白组上调,胃炎Ⅰ号大、中、小及维酶素组表达水平较模型组下调。
2.临床研究:两组在性别、年龄段、病程段等方面比较无统计学意义(P均＞0.05),提示两组具有可比性。中医证候量表调查显示,治疗前两组各症状比较无统计学意义(P均＞0.05)。治疗后两组各症状比较,胃炎Ⅰ号方对于改善痞满胀闷、胃脘疼痛、口干口苦、嗳气反酸、大便稀溏方面与维酶素有差异(P均＜0.05)。二者在改善纳呆乏力症状方面无统计学意义;治疗组和对照组各症状治疗前后比较,胃炎Ⅰ号方和维酶素均能改善各临床症状(P均＜0.05)。两者在改善胃脘疼痛、嗳气反酸、口干口苦、大便箱绶矫嫖秆注窈欧接庞谖杆?在痞满胀闷、纳呆乏力方面两者无差别。两组中医疗效比较有统计学意义(P=0.045),胃炎Ⅰ号方疗效优于维酶素。
结论:
1.胃炎Ⅰ号方对改善胃癌前病变大鼠一般情况,以及胃粘膜慢性炎症,逆转腺体萎缩、肠上皮化生等方面均有一定疗效。胃炎Ⅰ号方对改善大鼠胃癌前病变组织异常的超微结构有一定的作用。
2.胃炎Ⅰ号方治疗胃癌前病变的机制可能是降低MMP-7mRNA、MMP-9mRNA的表达,使大鼠胃组织MMP-7、MMP-9蛋白的表达下调,以及降低MMP-7、MMP-9酶的活性,多个环节共同起作用所致。
3.胃炎Ⅰ号方和维酶素均能改善患者临床症状,两者中医疗效比较,胃炎Ⅰ号方疗效优于维酶素。
Background:Gastric cancer is a common cancer in the alimentary system.Its incidence rate and cancer mortality is the second place among the world's incidence rate and cancer mortality,so it has became a serious threat to human health.Because we don' t know its pathogen and pathogenesis,we could not prevent the disease according to the pathogenesis.Gastric mucosa cancerization always go though long precancerous phase.The pathological changes had shown the general trend that from chronic superficial gastritis to chronic atrophia gastritis,then intestines epidermis vegetates and atypical hyperplasia.The intestines epidermis vegetate and atypical hyperplasia were named as gastric precancerous lesion.So preventing and treating gastric precancerous lesions is the key of the secondary prevention. If we can diagnose and treat the disease in the gastric precancerous stage, cancer mortality should be decline greatly.Chinese medcine demonstrates advantages in preventing and treating precancerous lesions.According to the theory of Traditional Chinese Medicine(TCM) which spleen and stomach are the postnatal base and the sources for the production and transformation of qi and blood,Professor Liu Youzhang created the TCM compound formula named as WeiYanIHao(WYIH) after the long-term clinical practice.Preliminary clinical researches have shown that WYIH have significant curative effect on the chronic atrophic gastritis patients with weakness of the spleen and the stomach. Preliminary animal experiment have shown that WYIH have significant curative effect on the CAG model rats,as well as reverse intestines epidermis vegetate to some extent.The purpose of this research is to study the possible mechanism.In recent years,several studies have shown that Matrix metalloproteinase(MMPs) can be expressed excessively in gastric cancer.MMPs are endogenic proteolytic enzyme,Which participate in tissue reconstruct,cell proliferation,malignant cell infiltration,and metastasis by means of degrading extracellular matrix,regulating cell adhesion,and promoting vascularization,et al.As the important members of MMPs famility,MMP-7 and MMP-9 had been proved that their excessive expression and increasing activity are connected closely with tumorous growing,immersion,and transferring. Previous researches have shown that the expressions of MMP-7,9 in gastric precancerous lesions are higher than those expressions in the chronic gestritis tissue.Are the control mechanisms that the WYIH formula treat the gastric precancerous lesion related to MMP-7,9? These will be the focus of the experiment.
Objective:According to the clinical research,we will draw out an impersonal and fair conclusion on WYIH clinical effects.The animal experiment which provide theoretical basis for clinical working is to explore the possible mechanism of WYIH formula on treatment of gastric precancerous lesions by means of studying the expression of MMPs with the molecular biology techniques and immunohistochemistry technique.
Methods:
1.Animal experiment:84 rats were randomly divided into six groups:model group,normal group,large dose WYIH group,medium dose WYIH group,small dose WYIH group,and WeiMeiSu(WMS) group.Each groups had 12 rats,but model group had 24 rats.Normal group was given normal water,diet and the same volume of 0.9%saline.Other groups freely drank 50μg/mL N-methyl-N'-nitro-nitrosoguanidine (MNNG) solution,without other water during the produced animal model phase;and were drunk with ranitidine hydrochloride at 0.03g/kg one time a day;and were given hunger-satiety disorders(animals were fed with adequate food for 2 days and not given food for 1 day).A total of 20 weeks were spent for produced animal model.After the animal model was successfully produced,WYIH large,medium and small dose group were given WYIH separately in the dose of 2.16g/(kg·d),1.08g/(kg·d),0.54g/(kg·d).WMS group was given WMS decoction in the dose of 0.86g/(kg·d).Normal group and model group were given 0.9%saline in the dose of 0.18g/(kg·d).At the end of the 3 months experiment,the general state of rats' health and histopathological examination of stomach were observed,as well as the expression and activity of MMP-7,MMP-9 of gastric tissue were observed by the three methods of immunohistochemistry,gelatin zymography and polymerase chain reaction technique.
2.Clinical observations:30 cases were selected and randomly divided into two groups:WYIH group and WMS group.Before and after the treatment,the clinical symptoms and drug safety were compared to know the effect of WYIH by the table of TCM symptom schedule.
Results:
1.Animal experiment:
The abnormalities of the rat' s gastric mucosa included gland atrophy, intestinal metaplasia,and atypical hyperplasia,which shown the animal model was successfully produced.After the treatment of WYIH and WMS,these histological abnormalities were lessened.
Compared with model group,on the expression of MMP-7 in gastric tissue, normal group was statistically significant(P=0.000);large dose WYIH group, medium dose WYIH group,small dose WYIH group and WMS group were statistically significant(P=0.000,P=0.000,P=0.005,P=0.032).There were not significant differences between large dose WYIH group,medium dose WYIH group and small dose WYIH group.There were significant differences between medium dose WYIH group and WMS group(P=0.032);but there were no differences between large dose WYIH group,small dose WYIH group and WMS group(P=0.093,P=0.466).
Compared with model group,normal group were statistically significant on the expression of MMP-9 in gastric tissue(P=0.001);large dose WYIH group, medium dose WYIH group,small dose WYIH group and WMS group were statistically significant(P=0.002,P=0.000,P=0.002,P=0.012).There were not significant differences between large dose WYIH group,medium dose WYIH group,small dose WYIH group and WMS group.
There were significant differences among each group for the activity of MMP-7 in gastric tissue(P=0.000).From the mean rank trend,the activity of MMP-7 of model group was higher than others groups,and the activity of MMP-7 of normal group was lowest in the groups.The activity of MMP-7 of medium dose WYIH group was lower than large dose WYIH group,small dose WYIH group and WMS group.
There were significant differences among each group for the activity of MMP-9 in gastric tissue(P=-0.000).From the mean rank trend,the activity of MMP-9 of model group was higher than others groups,and the activity of MMP-9 of normal group was lowest in the groups.The activity of MMP-9 of medium dose WYIH group was lower than large dose WYIH group,small dose WYIH group and WMS group.
There are significant differences among each of group for the expression of MMP-7mRNA in gastric tissue(P<0.05).From the mean rank trend,the expression of MMP-7 of model group was higher than normal group,and large dose WYIH group,medium dose WYIH group,small dose WYIH group and WMS group were lower than model group on the expression of MMP-7.
There are significant differences among each of group for the expression of MMP-9mRNA in gastric tissue(P<0.05).From the mean rank trend,the expression of MMP-9 mRNA of model group was higher than normal group,and large dose WYIH group,medium dose WYIH group,small dose WYIH group and WMS group were lower than model group on the expression of MMP-9mRNA.
2.Clinical observations:
The differences among sex,age and course of disease were not significant between WYIH group and WMS group(P>0.05).So these two groups are comparable. There were no differences of clinical symptoms by estimating table of TCM symptom schedule before treatment(P>0.05).The differences of stuffiness and fullness,stomachpain,dry mouth and thirst,belching and acid regurgitation,sloppy stool between the WYIH group and WMS group after treatment were significant(P<0.05).No difference of poor appetite and lack of strength between WYIH and WMS were found.The Differences of the items of TCM symptom schedule table were significant before and after treating with WYIH or WMS(P<0.05).WYIH and WMS can improve TCM symptoms such as stomachpain, belching and acid regurgitation,dry mouth and thirst,sloppy stool.The effect of WYIH was better than WMS.There was no difference in stuffiness and fullness, torpid intake and lack of strength between WYIH and WMS.The clinical curative effect of TCM between WYIH group and WMS group is significant(P=0.045),WYIH can improve symptom of TCM better than WMS.
Conclusion:
1.WYIH can improve general situation of rats,and treat and reverse the chronic inflammation of gastric mucosa,glands atrophy,and intestinal metaplasia. WYIH can improve the abnormal ultrastructure of gastric precancerous lesions rats.
2.WYIH can decrease the expression and activity of MMP-7 and MMP-9 in gastric tissue of gastric precancerous lesions rats,as well as WYIH can decrease the expression of MMP-7mRNA and MMP-9mRNk.These maybe the possible mechanism of WYIH formula on treatment of gastric precancerous lesions
3.Both WYIH and WMS can improve the clinical symptoms of patient.The clinical curative effect of TCM between WYIH group and WMS group is significant,WYIH can improve symptom of TCM better than WMS.
胃癌是消化系统常见的恶性肿瘤之一,位居全球肿瘤发病率和癌症病死率的第二位,严重威胁着人类的健康。然而其病因病机尚不明确,无法进行针对病因的一级预防,但胃粘膜的癌变往往经历较长的癌前病变阶段,呈现慢性浅表性胃炎一慢性萎缩性胃炎—肠上皮化生—不典型增生—癌变的趋势。其中,不典型增生和肠上皮化生被称为癌前病变。因此,针对癌前病变的二级预防是防治胃癌的关键。如果能在胃癌前病变阶段及早诊断,及早治疗,则能极大的降低胃癌的死亡率。中医药在防治胃癌前病变方面展示出独特的优势。胃炎Ⅰ号是导师刘友章教授根据中医脾胃为后天之本,气血生化之源的理论,结合临床,创制的纯中药复方。在临床应用中取得了很好的疗效。前期研究已初步证实了胃炎Ⅰ号对脾胃虚弱型慢性萎缩性(CAG)胃炎病人和CAG模型大鼠胃粘膜修复有很好的疗效,并有一定的抗肠上皮化生的作用。本课题拟研究胃炎Ⅰ号治疗胃癌前病变可能的作用机制。近年来许多研究证实胃癌中基质金属蛋白酶(MMPs)出现过度表达和活性提高。MMPs是内源性蛋白水解酶,它主要通过降解细胞外基质、调节细胞间黏附、以及促进新生血管形成等参与组织重构、细胞增殖、恶性细胞浸润、转移等。MMP-7、9是MMPs家族中重要成员,它们的过度表达或活性的提高与肿瘤的生长、浸润和转移等有密切关系。此外,一些研究已证明,MMP-7、9在癌前病变组织中的表达较慢性胃炎组织中的表达升高。那么,胃炎Ⅰ号方治疗胃癌前病变的机制是否与MMP-7、9有关?这将是本课题研究的重点。
研究目的:
本课题通过临床研究对胃炎Ⅰ号方临床疗效进行较为客观的评价,并使用分子生物学技术以及免疫组织化学技术等,观察大鼠胃组织中MMP-7、9蛋白的表达、酶的活性,以及MMP-7mRNA、MMP-9mRNA的表达,从而初步探索胃炎Ⅰ号治疗胃癌前病变可能的作用机制,为临床更好的使用该方提供理论依据。
研究方法:
1.动物实验:将84只大鼠,雌雄各半,按体重随机分为6组,模型组24只,空白组、胃炎Ⅰ号大、中、小剂量组及维酶素组各12只。造模期间,空白组给予正常饮食以及等体积生理盐水灌胃。其余各组给予以下处理措施:①50μg/mL N-甲基-N'-硝基-亚硝基胍(MNNG)溶液自由饮用,造模期间不再给予其他饮水;②盐酸雷尼替丁水溶液按每天0.03g/kg灌胃,每日1次;③饥饱失常:连续2d喂食,保证足量,1d停食。造模共20周。造模成功后,胃炎Ⅰ号大、中、小剂量组分别使用2.16g/(kg·d)、1.08g/(kg·d)、0.54g/(kg·d)的胃炎Ⅰ号水煎液灌胃。维酶素组用0.86g/(kg·d)的维酶素水溶液灌胃。空白组和模型组均用0.18g/(kg·d)的生理盐水灌胃。给药3个月。实验结束后观察大鼠一般情况,取胃组织做病理检查。使用免疫组化技术观察MMP-7、MMP-9蛋白的表达。使用明胶酶谱法观察MMP-7、MMP-9酶的活性。使用聚合酶链反应(PCR)技术观察MMP-7mRNA、MMP-9mRNA的表达。
2.临床观察:符合纳入标准的胃癌前病变患者30例,按就诊时间随机分为胃炎Ⅰ号治疗组和维酶素对照组,每组各15例。采用中医症候量表进行观察,比较两组治疗前后中医症状评分、两组患者的中医疗效,以及治疗后药物安全性观察。从而对胃炎Ⅰ号方治疗胃癌前病变的临床疗效做出客观的评价。
研究结果:
1.动物试验:病理结果显示大鼠胃粘膜腺体萎缩,伴有肠上皮化生和不典型增生,提示造模成功。经胃炎Ⅰ号和维酶素治疗后,上述病理改变减轻或消失。
大鼠胃组织MMP-7的表达:空白组与模型组比较有统计学意义(P=0.000)。大、中、小剂量组及维酶素组与模型组比较有统计学意义(P=0.000,P=0.000,P=0.005,P=0.032)。大、中、小剂量组之间无统计学意义,中剂量组与维酶素组之间有统计学意义(P=0.032)。大、小剂量组与维酶素组之间无统计学意义(P=0.093,P=0.466)。
大鼠胃组织MMP-9的表达:空白组与模型组比较有统计学意义(P=0.001)。大、中、小剂量组及维酶素组与模型组比较有统计学意义(P=0.002,P=0.000,P=0.002,P=0.012)。大、中、小剂量组及维酶素组之间无统计学意义。
大鼠胃组织MMP-7活性:χ~2=26.533,df=5,P=0.000,各组间差异有统计学意义。从平均秩次的变化趋势看模型组活性最高,空白组活性最低。中剂量组较大、小剂量组、维酶素组MMP-7活性低。
大鼠胃组织MMP-9活性:χ~2=24.386,df=5,P=0.000,各组间差异有统计学意义。从平均秩次的变化趋势看模型组MMP-9活性最高,空白组活性最低。中剂量组较大、小剂量组、维酶素组MMP-9活性低。
大鼠胃组织MMP-7mRNA表达:χ~2=11.730,df=5,P=0.039,各组间差异有统计学意义。从平均秩次的变化趋势看模型组MMP-9mRNA表达水平较空白组上调。胃炎Ⅰ号大、中、小剂量组和维酶素组较模型组表达水平下调。
大鼠胃组织MMP-9mRNA表达:χ~2=11.385,df=5,P=0.044,各组间差异有统计学意义。从平均秩次的变化趋势看模型组MMP-9mRNA表达水平较空白组上调,胃炎Ⅰ号大、中、小及维酶素组表达水平较模型组下调。
2.临床研究:两组在性别、年龄段、病程段等方面比较无统计学意义(P均＞0.05),提示两组具有可比性。中医证候量表调查显示,治疗前两组各症状比较无统计学意义(P均＞0.05)。治疗后两组各症状比较,胃炎Ⅰ号方对于改善痞满胀闷、胃脘疼痛、口干口苦、嗳气反酸、大便稀溏方面与维酶素有差异(P均＜0.05)。二者在改善纳呆乏力症状方面无统计学意义;治疗组和对照组各症状治疗前后比较,胃炎Ⅰ号方和维酶素均能改善各临床症状(P均＜0.05)。两者在改善胃脘疼痛、嗳气反酸、口干口苦、大便箱绶矫嫖秆注窈欧接庞谖杆?在痞满胀闷、纳呆乏力方面两者无差别。两组中医疗效比较有统计学意义(P=0.045),胃炎Ⅰ号方疗效优于维酶素。
结论:
1.胃炎Ⅰ号方对改善胃癌前病变大鼠一般情况,以及胃粘膜慢性炎症,逆转腺体萎缩、肠上皮化生等方面均有一定疗效。胃炎Ⅰ号方对改善大鼠胃癌前病变组织异常的超微结构有一定的作用。
2.胃炎Ⅰ号方治疗胃癌前病变的机制可能是降低MMP-7mRNA、MMP-9mRNA的表达,使大鼠胃组织MMP-7、MMP-9蛋白的表达下调,以及降低MMP-7、MMP-9酶的活性,多个环节共同起作用所致。
3.胃炎Ⅰ号方和维酶素均能改善患者临床症状,两者中医疗效比较,胃炎Ⅰ号方疗效优于维酶素。
Background:Gastric cancer is a common cancer in the alimentary system.Its incidence rate and cancer mortality is the second place among the world's incidence rate and cancer mortality,so it has became a serious threat to human health.Because we don' t know its pathogen and pathogenesis,we could not prevent the disease according to the pathogenesis.Gastric mucosa cancerization always go though long precancerous phase.The pathological changes had shown the general trend that from chronic superficial gastritis to chronic atrophia gastritis,then intestines epidermis vegetates and atypical hyperplasia.The intestines epidermis vegetate and atypical hyperplasia were named as gastric precancerous lesion.So preventing and treating gastric precancerous lesions is the key of the secondary prevention. If we can diagnose and treat the disease in the gastric precancerous stage, cancer mortality should be decline greatly.Chinese medcine demonstrates advantages in preventing and treating precancerous lesions.According to the theory of Traditional Chinese Medicine(TCM) which spleen and stomach are the postnatal base and the sources for the production and transformation of qi and blood,Professor Liu Youzhang created the TCM compound formula named as WeiYanIHao(WYIH) after the long-term clinical practice.Preliminary clinical researches have shown that WYIH have significant curative effect on the chronic atrophic gastritis patients with weakness of the spleen and the stomach. Preliminary animal experiment have shown that WYIH have significant curative effect on the CAG model rats,as well as reverse intestines epidermis vegetate to some extent.The purpose of this research is to study the possible mechanism.In recent years,several studies have shown that Matrix metalloproteinase(MMPs) can be expressed excessively in gastric cancer.MMPs are endogenic proteolytic enzyme,Which participate in tissue reconstruct,cell proliferation,malignant cell infiltration,and metastasis by means of degrading extracellular matrix,regulating cell adhesion,and promoting vascularization,et al.As the important members of MMPs famility,MMP-7 and MMP-9 had been proved that their excessive expression and increasing activity are connected closely with tumorous growing,immersion,and transferring. Previous researches have shown that the expressions of MMP-7,9 in gastric precancerous lesions are higher than those expressions in the chronic gestritis tissue.Are the control mechanisms that the WYIH formula treat the gastric precancerous lesion related to MMP-7,9? These will be the focus of the experiment.
Objective:According to the clinical research,we will draw out an impersonal and fair conclusion on WYIH clinical effects.The animal experiment which provide theoretical basis for clinical working is to explore the possible mechanism of WYIH formula on treatment of gastric precancerous lesions by means of studying the expression of MMPs with the molecular biology techniques and immunohistochemistry technique.
Methods:
1.Animal experiment:84 rats were randomly divided into six groups:model group,normal group,large dose WYIH group,medium dose WYIH group,small dose WYIH group,and WeiMeiSu(WMS) group.Each groups had 12 rats,but model group had 24 rats.Normal group was given normal water,diet and the same volume of 0.9%saline.Other groups freely drank 50μg/mL N-methyl-N'-nitro-nitrosoguanidine (MNNG) solution,without other water during the produced animal model phase;and were drunk with ranitidine hydrochloride at 0.03g/kg one time a day;and were given hunger-satiety disorders(animals were fed with adequate food for 2 days and not given food for 1 day).A total of 20 weeks were spent for produced animal model.After the animal model was successfully produced,WYIH large,medium and small dose group were given WYIH separately in the dose of 2.16g/(kg·d),1.08g/(kg·d),0.54g/(kg·d).WMS group was given WMS decoction in the dose of 0.86g/(kg·d).Normal group and model group were given 0.9%saline in the dose of 0.18g/(kg·d).At the end of the 3 months experiment,the general state of rats' health and histopathological examination of stomach were observed,as well as the expression and activity of MMP-7,MMP-9 of gastric tissue were observed by the three methods of immunohistochemistry,gelatin zymography and polymerase chain reaction technique.
2.Clinical observations:30 cases were selected and randomly divided into two groups:WYIH group and WMS group.Before and after the treatment,the clinical symptoms and drug safety were compared to know the effect of WYIH by the table of TCM symptom schedule.
Results:
1.Animal experiment:
The abnormalities of the rat' s gastric mucosa included gland atrophy, intestinal metaplasia,and atypical hyperplasia,which shown the animal model was successfully produced.After the treatment of WYIH and WMS,these histological abnormalities were lessened.
Compared with model group,on the expression of MMP-7 in gastric tissue, normal group was statistically significant(P=0.000);large dose WYIH group, medium dose WYIH group,small dose WYIH group and WMS group were statistically significant(P=0.000,P=0.000,P=0.005,P=0.032).There were not significant differences between large dose WYIH group,medium dose WYIH group and small dose WYIH group.There were significant differences between medium dose WYIH group and WMS group(P=0.032);but there were no differences between large dose WYIH group,small dose WYIH group and WMS group(P=0.093,P=0.466).
Compared with model group,normal group were statistically significant on the expression of MMP-9 in gastric tissue(P=0.001);large dose WYIH group, medium dose WYIH group,small dose WYIH group and WMS group were statistically significant(P=0.002,P=0.000,P=0.002,P=0.012).There were not significant differences between large dose WYIH group,medium dose WYIH group,small dose WYIH group and WMS group.
There were significant differences among each group for the activity of MMP-7 in gastric tissue(P=0.000).From the mean rank trend,the activity of MMP-7 of model group was higher than others groups,and the activity of MMP-7 of normal group was lowest in the groups.The activity of MMP-7 of medium dose WYIH group was lower than large dose WYIH group,small dose WYIH group and WMS group.
There were significant differences among each group for the activity of MMP-9 in gastric tissue(P=-0.000).From the mean rank trend,the activity of MMP-9 of model group was higher than others groups,and the activity of MMP-9 of normal group was lowest in the groups.The activity of MMP-9 of medium dose WYIH group was lower than large dose WYIH group,small dose WYIH group and WMS group.
There are significant differences among each of group for the expression of MMP-7mRNA in gastric tissue(P<0.05).From the mean rank trend,the expression of MMP-7 of model group was higher than normal group,and large dose WYIH group,medium dose WYIH group,small dose WYIH group and WMS group were lower than model group on the expression of MMP-7.
There are significant differences among each of group for the expression of MMP-9mRNA in gastric tissue(P<0.05).From the mean rank trend,the expression of MMP-9 mRNA of model group was higher than normal group,and large dose WYIH group,medium dose WYIH group,small dose WYIH group and WMS group were lower than model group on the expression of MMP-9mRNA.
2.Clinical observations:
The differences among sex,age and course of disease were not significant between WYIH group and WMS group(P>0.05).So these two groups are comparable. There were no differences of clinical symptoms by estimating table of TCM symptom schedule before treatment(P>0.05).The differences of stuffiness and fullness,stomachpain,dry mouth and thirst,belching and acid regurgitation,sloppy stool between the WYIH group and WMS group after treatment were significant(P<0.05).No difference of poor appetite and lack of strength between WYIH and WMS were found.The Differences of the items of TCM symptom schedule table were significant before and after treating with WYIH or WMS(P<0.05).WYIH and WMS can improve TCM symptoms such as stomachpain, belching and acid regurgitation,dry mouth and thirst,sloppy stool.The effect of WYIH was better than WMS.There was no difference in stuffiness and fullness, torpid intake and lack of strength between WYIH and WMS.The clinical curative effect of TCM between WYIH group and WMS group is significant(P=0.045),WYIH can improve symptom of TCM better than WMS.
Conclusion:
1.WYIH can improve general situation of rats,and treat and reverse the chronic inflammation of gastric mucosa,glands atrophy,and intestinal metaplasia. WYIH can improve the abnormal ultrastructure of gastric precancerous lesions rats.
2.WYIH can decrease the expression and activity of MMP-7 and MMP-9 in gastric tissue of gastric precancerous lesions rats,as well as WYIH can decrease the expression of MMP-7mRNA and MMP-9mRNk.These maybe the possible mechanism of WYIH formula on treatment of gastric precancerous lesions
3.Both WYIH and WMS can improve the clinical symptoms of patient.The clinical curative effect of TCM between WYIH group and WMS group is significant,WYIH can improve symptom of TCM better than WMS.
引文
[1]叶任高,陆再英.内科学[M],北京:人民卫生出版社,2000,第5版:410.
[2]Marchenko GN,Strongin AY.MMP-28,a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors.Gene.2001;265:87-93.
[3]刘鹏飞,刘顺英,钱建忠等.PPAR γ和MMP-7与胃癌及癌前病变的关系.中华消化内镜杂志.2005:22(3):171-173.
[4]李岩,蒋小猛,王少峰.幽门螺杆菌感染与不同胃粘膜病变中基质金属蛋蛋白酶9表达的关系.中国血液流变学杂志.2005:15(1):50-51.
[5]周秉舵,朱生梁.辨治慢性萎缩性胃炎经验[J].上海中医药杂志,2007:41(2):19-21.
[6]陈伟,刘华一.治疗慢性萎缩性胃炎经验[J].辽宁中医杂志,2008;35(3):340-341.
[7]崔儒涛,蔡淦.逆转胃癌前病变的经验[J].中医杂志,1999;40(7):398-399.
[8]张声生.中医治疗慢性萎缩性胃炎及胃癌前病变的思路[J].江苏中医药,2007;39(8):3-4.
[9]陈伟,刘华一.治疗慢性萎缩性胃炎经验[J].辽宁中医杂志,2008;35(3):340-341.
[10]张子明,张继泽.治疗慢性萎缩性胃炎经验撷要[J].四川中医,2006;24(8):5-7.
[11]代二庆,张磊,孙捍卫等.袁红霞教授辨治慢性萎缩性胃炎(CAG)特点探析[J].陕西中医,2007;28(1):85-87.
[12]郭遂成,孙杰.参七芍草汤治疗慢性萎缩性胃炎63例[J].陕西中医,2008;29(1):28-29.
[13]蒋民主,张兰,曾英.健脾活血清热方治疗胃癌前病变的临床疗效观察[J].中国中西医结合消化杂志,2001;9(6):369.
[14]吕长生.柴芍六君丹七汤治疗慢性萎缩性胃炎38例临床观察[J].中医药导报,2008;14(2):27,47.
[15]郭云协,李芳.健脾消积汤治疗萎缩性胃炎58例[J].新中医,2008;40(4):73.
[16]尤金亮,尤俊文.半夏泻心汤加昧治疗慢性萎缩性胃炎60例临床观察[J].宁夏医学院学报,2007;29(4):433-434.
[17]陈苑玲,潘一滨,蔡淦.胃二方加减治疗胃癌前病变30例临床研究[J].中医杂志,2002;43(4):257-276.
[18]Ito M,Haruma K,KamadaTetal.Helicobacter priori eradicationtherapy improves atrophic gastritis and intestinal metaplasia:a 5-year prospective study of patients with atrophi gastritis.AlimentPharmacol Ther,2002;16(8):1449-1456.
[19]Leung WK,Lin SR,Ching JY etal.Factors predicting progression of gastric intestinal metaplasia:results of a randomized trial on Heli-cobacter pylori eradication.Gut,2004;53(9):1244-1249.
[20]石雪迎,赵凤志,戴欣等.三七对胃癌前病变大鼠胃液分泌功能及胃粘膜保护因素的影响[J].中医杂志,2002;43(4):296-298.
[21]王松坡,蔡淦,窦丹波,等.乐胃煎对大鼠胃癌前病变胃粘膜异型性的影响[J].中国中西医结合消化杂志,2001;9(3):145-147.
[22]李守朝,王峰,蔺焕萍,等.参佛胃康对慢性萎缩性胃炎大鼠血清胃泌素和血浆胃动素水平的影响.江西中医药,2007;38(12):68-69.
[23]王玲玲,贾占东,龚占悦,等.益胃消增胶囊对CAG大鼠胃粘膜PGE2和血清胃动素的影响[J].中华中医药学刊,2008;26(2):387-389.
[24]南杏初,胡运莲,李秋华,等.加味左金丸对大鼠胃癌前病变环氧合酶-2蛋白表达的影响[J].湖北中医学院学报,2007;9(1):34-36.
[25]蔡锦莲,李爱娣,曾兰英.萎胃散对慢性萎缩性胃炎患者EGF和GH的影响[J].中医药学刊,2006;24(7):1266-1268.
[26]王垂杰,李岩,任明智.阻癌胃泰对胃癌前病变大鼠胃窦部P物质、血管活性肠肽和降钙素基因相关肽的影响[J].中国中西医结合杂志,2006;26:92-94.
[27]张伟,贾会珍,王志坤.小归芍超临界提取物对大鼠胃癌前病变抗氧化水平的影响[J].中药药理与临床,2008;24(1):59-61.
[28]王春生,刘亚军,周晶.开痞合剂对实验性慢性萎缩性胃炎大鼠NO、MDA、SOD的影响[J].北京中医,2005;24(4):249-250.
[29]陈大权,王文仲,李谈等.胃神口服液对胃癌前病变大鼠IL-2 NK细胞的影响[J].中华中医药学刊,2007;25(2):306-307.
[30]刘启泉,孙世华,杜艳茹.解毒活血法对胃癌前病变患者免疫球蛋白的影响[J].河北中医,2007;29(3):201-202.
[31]黄晋红,张仲海,黄宗明.消萎灵Ⅰ号胶囊对慢性萎缩性胃炎及胃癌前病变组织DNA 含量的影响[J].山东中医药大学学报,2002:26(2):114-115.
[32]吕志刚,白兆芝,徐列明等.胃安泰胶囊对胃癌前期病变大鼠胃粘膜细胞核仁组成区嗜银蛋白水平的影响[J].中国中西医结合消化杂志,2006:14(2):108-110.
[33]谢晶日,梁国英,李晨阳,等.胃灵一号冲剂对大鼠胃癌前病变端粒酶影响的实验研究[J].医学创新研究,2007:4(32):25-26.
[34]胡玲,劳绍贤,周福生,等.胃炎消对胃癌癌前病变相关靶基因蛋白表达的调控作用.浙江中西医结合杂志,2001;11(6):334-36.
[35]胡玲,劳绍贤,王建华.胃炎消对胃癌癌前病变bcl_2癌基因mRNA表达的影响.上 海中医药杂志,2006:40(1):27-28.
[36]王晓梅,王瑞丽,刘俊田,等.金果胃康颗粒对胃癌前病变大鼠胃粘膜基因蛋白(P53、c-myc)表达的影响[J].山西中医,2003;19(3):49-50.
[37]卓玉珍,袁红霞,袁红梅,等.善胃系列方治疗胃癌前病变的相关基因蛋白表达试验研究[J].天津中医学院学报,2006:25(1):18-21.
[38]魏爱勤,魏秀芹,袁红霞,等.善胃Ⅰ号方治疗血瘀热毒型胃癌前病变的临床疗效及对EGF、PCNA的影响[J].新中医,2008:40(2):32-34.
[39]常东,劳绍贤,胡玲.胃炎消对胃癌癌前病变患者细胞周期素依赖性激酶及PCNA和Ki-67蛋白表达的影响[J].中国中西医结合消化杂志,2005:3{5}:284-286.
[40]赵玉斌,肖颖,李佃贵.解毒化浊和胃方阻断大鼠CAG癌前病变的分子生物学机制[J].疑难病杂志,2008;(1):30-32.
[41]梅武轩,常春,余娜.益气化瘀中药对大鼠胃癌前病变蛋白激酶C及细胞周期素E蛋白表达的影响[J].中国中医药信息杂志,2008:5(3):26-27.
[42]刘旺根,守东,冯黎.胃康舒宁对胃癌前病变大鼠胃粘膜上皮细胞凋亡及其相关调控基因表达的影响[J].河南中医,2007:7(9):20-22.
[43]郭喜军,栾英辉,王芩.胃痞颗粒对胃癌癌前病变患者胃粘膜上皮细胞凋亡及Bcl-2 P53 Fas蛋白表达的影响[J].中国药物与临床,2006:6(1):742-744.
[44]傅志泉,黄谦,黄巧玲,等.和胃口服液对萎缩性胃炎大鼠胃粘膜萎缩及细胞凋亡影响的实验研究[J].中国中医药科技,2008:15(1):18-19.
[45]曹志群,张卫东,孙阂等.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠血管生成因子、VEGF的影响[J].光明中医,2008:23(1):15-17.
[46]刘旺根,蒋时红.黄芪建中汤干预脾虚型慢性萎缩性胃炎大鼠胃粘膜表皮生长因子含量、诱导型一氧化氮合成酶和表皮生长因子受体基因的表达[J].中国临床康复,2006:10(43):123-125.
[47]胡运莲,姜楠,谭大琦.加味左金丸对大鼠胃癌前病变胃粘膜EGFR、VEGF、C-met、Bcl-2、P53表达的影响[J].世界华人消化杂志,2006;14(7):650-654.
[48]陈更新,李合国.养正散结汤对慢性萎缩性胃炎癌前病变胃粘膜EGF、EGFR的影响[J].中医药导报,2007:13(12):20-22.
[49]丁松泽,李怀斌,黄河.幽门螺杆菌感染时致炎性因子的研究进展[J].新消化病学杂志,1995:3:221-222.
[50]徐克强,张万岱,周殿元,等.幽门螺杆菌致病中的作用研究[J].新消化病学杂志,1997;5:447.
[51]梁后杰,高晋华,刘为纹,等.幽门螺杆菌培养滤液长期作用下大鼠胃粘膜组织学的变化[J].世界华人消化杂志,1999;7:861-863.
[52]Xu CP,Gui XY,Liu W W,et al.Influence of Helicobacter pylori on gastric mucosal barrier.China Nati J New Gastroenterol,1995;1:41-42.
[53]Tsugane S,Kabuto M,Imai H,et al.Helicobaeter pylori,dietary facters,and atrophic gastritis in five Japanese populations with different gastric cancer mortality[J].Cancer Causes Control,1993;4:297-305.
[54]Kneller RW,Guo WD,Hsing AW,et al.Risk factors for stomach can-cer in sixty-five Chinese counties.Cancer Epideiol Biomarkers Prev,1992;1:113-118.
[55]Lynch DAF et al.Cell proliferation in Helicbacter pylori associated gastritis and the effect of eradication therapy[J].Gut,1995;36:346-350.
[56]Penella C etal.Proliferative activity of gastric epithelium in progressive stages of Helicobacter pylori infection.Dig Dis Sei,1996;41:1132-1138.
[57]汤建华,吕农华,谢勇,等.A study on interaction among Helicobacter pylori infection,gastric epithelial cytokinetics and its regulatory genes in gastric mucosa lesions.胃肠病学,2000;5(Suppl):A112-A113.
[58]祝荫,吕农华,陈江,等.胃粘膜癌变过程中幽门螺杆菌感染与hTERT及c-myc蛋白的关系.现代消化及介入诊疗,2003:8(1):35-37.
[59]吕农华,祝荫,陈江,等.根除幽门螺杆菌对端粒酶相关基因及c-myc蛋白表达的影响.中华消化杂志,2004:24(4):199-202.
[60]舒徐,吕农华,祝荫,等.幽门螺杆菌感染和P53蛋白的表达在胃粘膜病变中的关系.实用临床医学,2004:5(10):1-3.
[61]涂燕平,吕农华,谢勇,等.胃癌及癌前病变中P27kipl与转化生长因子β1之间关系的研究.胃肠病学,2002:7(增刊):A40.
[62]涂燕平,吕农华,谢勇,等.幽门螺杆菌感染与胃粘膜病变中P27kipl之间关系的研究.中华医学杂志,2002:82(增刊):123.
[63]熊碧芳,方向明,彭波,等.端粒酶RNA与胃粘膜HpcagA及增殖细胞核抗原表达的关系.临床内科杂志,2001:18(2):122-124.
[64]Kameshima H,Yagihashi A,Yajima T etal.Helicobacter pylori infection:augmentation of telomerase activity in cancer and noncancerous tissues.World J Surg,2000;24(10):1243 -1249.
[65]Farinati F,Cardin R,Oegan P,et al.0xidative DNA damage accumulation in gastric carcinogenesis.Gut,1998;42(3):351-356.
[66]房殿春,罗元辉,鲁荣,等.胃癌组织H-ras基因点突变与预后的关系[J].新消化病学杂志.1994:2(2):80-81.
[67]张红沽,赵志泉,王颖.胃粘膜组织中Bcl-2、Bax蛋白表达与胃癌的关系[J].河北医学,2001:7(10):865-873.
[68]Wang W,Luo HS,Yu BP.Telomerase and colorectal cancer[J].Shi jie Huaren Xiaohua Zazhi,2000;8:800.
[69]Burger AM,Mibby MC,Double JA.Telomerase activity in normal and malignant mammalian tissues:feasibility of telomerase as a target for cancer chemotherapy[J].Br J Cancer,1997:75:516.
[70]唐发清,蒋海鹰,段朝军,等.鼻咽上皮癌变过程中端粒酶活性和端粒酶RNA的表达[J].中华病理学杂志,2001:30:125.
[71]Kumakl F,Kawal T,Hirol S,et al.Telomerase activity and telomerase RNA component and hman telomerase reverse transcriptase in lung carci-nomas[J].Hum Pathol,2001;32:188.
[72]金梅,张维萍,罗元平,等.端粒酶基因在胃癌前病变的表达[J].中国实验诊断学.2005:9(2):219-220.
[73]沈汉澄.胃癌前病变WHO新标准与综合干预[J].浙江临床医学.2007:9(11):1441-1442.
[74]刘海峰,刘为纹,房殿春,等.幽门螺杆菌感染与胃癌前病变演化的关系[J].世界华人消化杂志,2002:20(8):912-915.
[75]Correa P,Fontham ET,Bravo JC etal.J Natl Cancer Inst,2000;92:1881-1882.
[76]Dixon MF.Gut,2001;49:2-4.
[77]靳桂艳.胶体果胶铋胶囊对胃癌前病变Bcl-2、P53基因蛋白影响的研究[J].中国医疗前沿.2007;1(2):52-54.
[78]胡品津,张汝逢.维酶素治疗慢性萎缩性胃炎疗效观察[J].新医学,1986:17(9):475-476.
[79]卢方,吴允华.联合叶酸和维霉素治疗慢性萎缩性胃炎疗效观察[J].浙江预防医学,2005:17(5):64-65.
[80]孟宪镛.胃癌癌前病变和胃癌相关疾病[J].交通医学,2006:20(4):364.
[81]李春启,刘为纹,房殿春,等.维甲酸对大鼠实验室性胃粘膜癌前病变的逆转、治疗作用[J].中华消化杂志,1994:14(6):319-322.
[82]李春启,刘为纹.丁酸钠治疗胃粘膜癌前病变的实验研究[J].中国肿瘤临床,1995;22(11):806-810.
[83]林瑶光.叶酸、维甲酸对胃癌前病变、胃癌逆转作用及抑癌机制[J].临床消化病杂志,2001:1:41.
[84]孙崇泉,冒云,陈明坤.叶酸对胃粘膜不典型增生的逆转作用[J].实用医技杂志,2003:10(4):335.
[85]Dannenberg AJ,Subbaramaiah K.Targeting cyclooxygenase-2 in human neoplasia:rationale and promise.Cancer cell,2003;4:431-436.
[86]Hu PJ,Yu J,Zeng ZR,et al.Chemoprevention of gastric cancer by celecoxib in rats.Gut,2004;53:195-200.
[87]Leung WK,Ng EK,Chan FK,et al.Effects of long-term rofecoxib on gastric intestional metaplasia:results of a randomized controlled trial,Clin Cancer Res,2006;12:4766-4722.
[88]Peraino C,Stafeldt EF,Cames BA,et al.Characterization of histochemically detectable altered hepatocycte foci and their relation to hepatic tumorigenesis in rats treated once with diethylnitrosaminer or benzo(a)pyrene with in one day after birth[J].Cancer Res,1984;44(8):3340-3347.
[89]Mitaka T,Tuskada H.Sexual difference in the histochemical characteristics of "altered cell foei" in liver of aged fischer 344 rats[J].Jpn J Cancer Res,1987;78(8):785-790.
[90]高进.肿瘤学基础与研究方法[M],北京:人民卫生出版社,1999;130.
[91]张新,范刚启.穴位注射对大鼠实验性胃癌前病变胃粘膜损伤的防治作用及对前列腺素E2、生长抑素的影响.浙江中医杂志,2006:41(12):698-699.
[92]王茵萍,查玮,孙茂峰,等.穴注黄芪、当归注射液对大鼠胃癌前病变胃粘膜上皮细胞影响的定量分析.天津中医,2002:19(5):58-60.
[93]孟振行,雷道年.亚硝基胍诱发大鼠胃腺癌发生和发展过程中病理学观察[J].临床与实验病理学杂志,1998:14(2):169-170.
[94]陈飞松,李春梅,任蜀兵,等.芪龙方防治大鼠胃癌癌前疾病的作用[J].中国中西医结合脾胃杂志,1999:7(2):68-71.
[95]Watenable T,Tada M,Nagai H,et al.Helicobacter priori infection induces gastric cancer in mongolian gerbils[J].Gastrenterology,1998;115(3):642-648.
[96]迟晶,傅宝玉.砂土鼠胃粘膜幽门螺杆菌长期感染的病理改变[J].世界华人消化杂志,2002:10(4):415.
[97]Drazek ES,Dubois A,Holmes RK.Characterization and presumptive identification of Helicobacter pylori isolates from rhesus monkeys[J].Clin Microbiol,1994;32(7):1799-1804.
[98]王晓梅,王瑞丽,刘俊田,等.金果胃康颗粒对胃癌前病变大鼠胃粘膜基因蛋白(P53、c-myc)表达的影响.山西中医,2003;19(3):49-50.
[99]Watanable H.Experimental induced intestinal eletaplasha in Wistar rats by x-ray radiation[J].Gastroenterology,1978;15:793.
[100]鲁香风,赵风志.中药治疗实验性慢性萎缩性胃炎的酶组化及电镜观察[J].中国中西医结合脾胃杂志,2000;8(5):257.
[101]王德俊,谢强敏.养胃冲剂对大鼠萎缩性胃粘膜的保护作用[J].解剖学研 究,2001;23(4):323.
[102]杨鸿,侯家玉.胆汁反流致慢性萎缩性胃炎的实验.北京中医药大学学报,2001;24(5):26.
[103]陆为民,单兆伟,吴静,等.大鼠慢性萎缩性胃炎癌前病变气虚血瘀证动物模型的研制.南京中医药大学学报(自然科学版),2000;5(16):156-158.
[104]李晓斌,夏天,张仲海,等.中药消萎灵对大鼠慢性萎缩性胃炎胃粘膜血流量和血浆胃动素的影响.第四军医大学学报,2002;23(9):772-775.
[105]谢晶日,王海强,王静滨.胃灵冲剂对慢性萎缩性胃炎大鼠胃粘膜影响的实验研究.中国中医药科技,2006;13(5):311-312.
[106]范英昌等.大鼠脾气虚型慢性萎缩性胃炎动物模型的实验研究.天津医药,1994;2,86.
[107]孙敬方.动物实验学[M],北京:人民卫生出版社,2001,第1版:462-463.
[108]Kleiner DE,Stetler-stevenson WG.Matrix metalloproteinases and metastasis,Cancer Chmemother Pharmacol,1999;(43suppl):S42.
[109]Pileher B,Dumin J,Sudbeck B,et al.The activity of collagenase-1 is required for keratinocyte migration on a type Ⅰ collagen matrix.J Cell BioL,1997;137(6):1445
[110]Deryugina EI,Bourdon MA,Jungwirth K,et al.Functional activation of integrin alpha V beta in tumor cells expressing membrane-type 1 matrix metalloproteinase.Int J Caneer,2000;86(1):15.
[111]Abdel-Ghany M,Cheng HC,Elble RC,et al.The breast cancer beta 4 integrin and endothelial human CLCA2 mediatding metastasis.J Biol Chem,2001:276(27):25438.
[112]Kabashima Y,Kakeji Y,et al.Clinicopathologieal features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis.Clln Cancer Res,2000;6(9):3581.
[113]Sun JM,Zheng HC,Yang XF,et al.Relationship between expression of matrix metalloproteinase-7 and clinicopathobiological behaviors of gastric cancer.Shijie Huaren Xiaohua Zhazi,2003;11:1310-1313.
[114]胡端敏,冯一中,王少峰.COX-2与MMP-7蛋自在胃癌组织中的表达及临床意义[J].苏州大学学报,2008:28(1):82-84,87.
[115]王绪霖,缴稳玲,吕宫舜,等.抑制幽门螺杆菌中药初步筛选杂志,1994;14(9):534.
[116]卢慧卿,杨京玉,丛英杰,等.珍珠粉、珍珠层粉药用价值的比较[J].天然产物研究与开发,1991:3(3):35-42.
[117]权伍荣.蒲公英提取物对小鼠胃粘膜损伤的恢复作用[J].第延边大学农学学 报,2008,30(4):276-279.
[118]赵浩如,李瑞,林以宁,等.白花蛇舌草不同提取工艺对抗肿瘤活性的影响[J].中国药科大学学报,2002,33(6):510.
[119]夏文娟,吴文涛,李淑君.白花蛇舌草联合化疗治疗晚期恶性肿瘤的疗效分析[J].四川省卫生管理干部学院学报,2001;6:93.[J].中国中西医结合
[120]吴厚铭,黄胜余,劳霞飞,等.白花蛇舌草免疫多糖结构的研究[J].有机化学,1992;12(4):428-431.
[121]于新,杜志坚,陈悦娇,等.白花蛇舌草提取物抗氧化作用的研究[J].食品与发酵工业,2002;28(3):10-13.
[122]Laddawan Boonyarathanakornkit,Chun-tao Che,Harry H,Fong S,et al.Constituents of Croton crassifolius Roots[J].Planta medica,1988;61.
[123]黄国栋,黄媛华,唐丽君.砂仁挥发油对胃溃疡粘膜PAF表达的影响[J].中药材,2008:31(11):1714-1716.
[124]刘友章.胃炎Ⅰ号对萎缩性胃炎病人胃粘膜修复作用之研究.中医杂志,1995:36(增刊):197.
[125]蓝惠玲,刘友章.胃炎Ⅰ号方治疗慢性萎缩性胃炎30例疗效观察.广州中医药大学学报,2005;5(3):170-178.
[2]Marchenko GN,Strongin AY.MMP-28,a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors.Gene.2001;265:87-93.
[3]刘鹏飞,刘顺英,钱建忠等.PPAR γ和MMP-7与胃癌及癌前病变的关系.中华消化内镜杂志.2005:22(3):171-173.
[4]李岩,蒋小猛,王少峰.幽门螺杆菌感染与不同胃粘膜病变中基质金属蛋蛋白酶9表达的关系.中国血液流变学杂志.2005:15(1):50-51.
[5]周秉舵,朱生梁.辨治慢性萎缩性胃炎经验[J].上海中医药杂志,2007:41(2):19-21.
[6]陈伟,刘华一.治疗慢性萎缩性胃炎经验[J].辽宁中医杂志,2008;35(3):340-341.
[7]崔儒涛,蔡淦.逆转胃癌前病变的经验[J].中医杂志,1999;40(7):398-399.
[8]张声生.中医治疗慢性萎缩性胃炎及胃癌前病变的思路[J].江苏中医药,2007;39(8):3-4.
[9]陈伟,刘华一.治疗慢性萎缩性胃炎经验[J].辽宁中医杂志,2008;35(3):340-341.
[10]张子明,张继泽.治疗慢性萎缩性胃炎经验撷要[J].四川中医,2006;24(8):5-7.
[11]代二庆,张磊,孙捍卫等.袁红霞教授辨治慢性萎缩性胃炎(CAG)特点探析[J].陕西中医,2007;28(1):85-87.
[12]郭遂成,孙杰.参七芍草汤治疗慢性萎缩性胃炎63例[J].陕西中医,2008;29(1):28-29.
[13]蒋民主,张兰,曾英.健脾活血清热方治疗胃癌前病变的临床疗效观察[J].中国中西医结合消化杂志,2001;9(6):369.
[14]吕长生.柴芍六君丹七汤治疗慢性萎缩性胃炎38例临床观察[J].中医药导报,2008;14(2):27,47.
[15]郭云协,李芳.健脾消积汤治疗萎缩性胃炎58例[J].新中医,2008;40(4):73.
[16]尤金亮,尤俊文.半夏泻心汤加昧治疗慢性萎缩性胃炎60例临床观察[J].宁夏医学院学报,2007;29(4):433-434.
[17]陈苑玲,潘一滨,蔡淦.胃二方加减治疗胃癌前病变30例临床研究[J].中医杂志,2002;43(4):257-276.
[18]Ito M,Haruma K,KamadaTetal.Helicobacter priori eradicationtherapy improves atrophic gastritis and intestinal metaplasia:a 5-year prospective study of patients with atrophi gastritis.AlimentPharmacol Ther,2002;16(8):1449-1456.
[19]Leung WK,Lin SR,Ching JY etal.Factors predicting progression of gastric intestinal metaplasia:results of a randomized trial on Heli-cobacter pylori eradication.Gut,2004;53(9):1244-1249.
[20]石雪迎,赵凤志,戴欣等.三七对胃癌前病变大鼠胃液分泌功能及胃粘膜保护因素的影响[J].中医杂志,2002;43(4):296-298.
[21]王松坡,蔡淦,窦丹波,等.乐胃煎对大鼠胃癌前病变胃粘膜异型性的影响[J].中国中西医结合消化杂志,2001;9(3):145-147.
[22]李守朝,王峰,蔺焕萍,等.参佛胃康对慢性萎缩性胃炎大鼠血清胃泌素和血浆胃动素水平的影响.江西中医药,2007;38(12):68-69.
[23]王玲玲,贾占东,龚占悦,等.益胃消增胶囊对CAG大鼠胃粘膜PGE2和血清胃动素的影响[J].中华中医药学刊,2008;26(2):387-389.
[24]南杏初,胡运莲,李秋华,等.加味左金丸对大鼠胃癌前病变环氧合酶-2蛋白表达的影响[J].湖北中医学院学报,2007;9(1):34-36.
[25]蔡锦莲,李爱娣,曾兰英.萎胃散对慢性萎缩性胃炎患者EGF和GH的影响[J].中医药学刊,2006;24(7):1266-1268.
[26]王垂杰,李岩,任明智.阻癌胃泰对胃癌前病变大鼠胃窦部P物质、血管活性肠肽和降钙素基因相关肽的影响[J].中国中西医结合杂志,2006;26:92-94.
[27]张伟,贾会珍,王志坤.小归芍超临界提取物对大鼠胃癌前病变抗氧化水平的影响[J].中药药理与临床,2008;24(1):59-61.
[28]王春生,刘亚军,周晶.开痞合剂对实验性慢性萎缩性胃炎大鼠NO、MDA、SOD的影响[J].北京中医,2005;24(4):249-250.
[29]陈大权,王文仲,李谈等.胃神口服液对胃癌前病变大鼠IL-2 NK细胞的影响[J].中华中医药学刊,2007;25(2):306-307.
[30]刘启泉,孙世华,杜艳茹.解毒活血法对胃癌前病变患者免疫球蛋白的影响[J].河北中医,2007;29(3):201-202.
[31]黄晋红,张仲海,黄宗明.消萎灵Ⅰ号胶囊对慢性萎缩性胃炎及胃癌前病变组织DNA 含量的影响[J].山东中医药大学学报,2002:26(2):114-115.
[32]吕志刚,白兆芝,徐列明等.胃安泰胶囊对胃癌前期病变大鼠胃粘膜细胞核仁组成区嗜银蛋白水平的影响[J].中国中西医结合消化杂志,2006:14(2):108-110.
[33]谢晶日,梁国英,李晨阳,等.胃灵一号冲剂对大鼠胃癌前病变端粒酶影响的实验研究[J].医学创新研究,2007:4(32):25-26.
[34]胡玲,劳绍贤,周福生,等.胃炎消对胃癌癌前病变相关靶基因蛋白表达的调控作用.浙江中西医结合杂志,2001;11(6):334-36.
[35]胡玲,劳绍贤,王建华.胃炎消对胃癌癌前病变bcl_2癌基因mRNA表达的影响.上 海中医药杂志,2006:40(1):27-28.
[36]王晓梅,王瑞丽,刘俊田,等.金果胃康颗粒对胃癌前病变大鼠胃粘膜基因蛋白(P53、c-myc)表达的影响[J].山西中医,2003;19(3):49-50.
[37]卓玉珍,袁红霞,袁红梅,等.善胃系列方治疗胃癌前病变的相关基因蛋白表达试验研究[J].天津中医学院学报,2006:25(1):18-21.
[38]魏爱勤,魏秀芹,袁红霞,等.善胃Ⅰ号方治疗血瘀热毒型胃癌前病变的临床疗效及对EGF、PCNA的影响[J].新中医,2008:40(2):32-34.
[39]常东,劳绍贤,胡玲.胃炎消对胃癌癌前病变患者细胞周期素依赖性激酶及PCNA和Ki-67蛋白表达的影响[J].中国中西医结合消化杂志,2005:3{5}:284-286.
[40]赵玉斌,肖颖,李佃贵.解毒化浊和胃方阻断大鼠CAG癌前病变的分子生物学机制[J].疑难病杂志,2008;(1):30-32.
[41]梅武轩,常春,余娜.益气化瘀中药对大鼠胃癌前病变蛋白激酶C及细胞周期素E蛋白表达的影响[J].中国中医药信息杂志,2008:5(3):26-27.
[42]刘旺根,守东,冯黎.胃康舒宁对胃癌前病变大鼠胃粘膜上皮细胞凋亡及其相关调控基因表达的影响[J].河南中医,2007:7(9):20-22.
[43]郭喜军,栾英辉,王芩.胃痞颗粒对胃癌癌前病变患者胃粘膜上皮细胞凋亡及Bcl-2 P53 Fas蛋白表达的影响[J].中国药物与临床,2006:6(1):742-744.
[44]傅志泉,黄谦,黄巧玲,等.和胃口服液对萎缩性胃炎大鼠胃粘膜萎缩及细胞凋亡影响的实验研究[J].中国中医药科技,2008:15(1):18-19.
[45]曹志群,张卫东,孙阂等.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠血管生成因子、VEGF的影响[J].光明中医,2008:23(1):15-17.
[46]刘旺根,蒋时红.黄芪建中汤干预脾虚型慢性萎缩性胃炎大鼠胃粘膜表皮生长因子含量、诱导型一氧化氮合成酶和表皮生长因子受体基因的表达[J].中国临床康复,2006:10(43):123-125.
[47]胡运莲,姜楠,谭大琦.加味左金丸对大鼠胃癌前病变胃粘膜EGFR、VEGF、C-met、Bcl-2、P53表达的影响[J].世界华人消化杂志,2006;14(7):650-654.
[48]陈更新,李合国.养正散结汤对慢性萎缩性胃炎癌前病变胃粘膜EGF、EGFR的影响[J].中医药导报,2007:13(12):20-22.
[49]丁松泽,李怀斌,黄河.幽门螺杆菌感染时致炎性因子的研究进展[J].新消化病学杂志,1995:3:221-222.
[50]徐克强,张万岱,周殿元,等.幽门螺杆菌致病中的作用研究[J].新消化病学杂志,1997;5:447.
[51]梁后杰,高晋华,刘为纹,等.幽门螺杆菌培养滤液长期作用下大鼠胃粘膜组织学的变化[J].世界华人消化杂志,1999;7:861-863.
[52]Xu CP,Gui XY,Liu W W,et al.Influence of Helicobacter pylori on gastric mucosal barrier.China Nati J New Gastroenterol,1995;1:41-42.
[53]Tsugane S,Kabuto M,Imai H,et al.Helicobaeter pylori,dietary facters,and atrophic gastritis in five Japanese populations with different gastric cancer mortality[J].Cancer Causes Control,1993;4:297-305.
[54]Kneller RW,Guo WD,Hsing AW,et al.Risk factors for stomach can-cer in sixty-five Chinese counties.Cancer Epideiol Biomarkers Prev,1992;1:113-118.
[55]Lynch DAF et al.Cell proliferation in Helicbacter pylori associated gastritis and the effect of eradication therapy[J].Gut,1995;36:346-350.
[56]Penella C etal.Proliferative activity of gastric epithelium in progressive stages of Helicobacter pylori infection.Dig Dis Sei,1996;41:1132-1138.
[57]汤建华,吕农华,谢勇,等.A study on interaction among Helicobacter pylori infection,gastric epithelial cytokinetics and its regulatory genes in gastric mucosa lesions.胃肠病学,2000;5(Suppl):A112-A113.
[58]祝荫,吕农华,陈江,等.胃粘膜癌变过程中幽门螺杆菌感染与hTERT及c-myc蛋白的关系.现代消化及介入诊疗,2003:8(1):35-37.
[59]吕农华,祝荫,陈江,等.根除幽门螺杆菌对端粒酶相关基因及c-myc蛋白表达的影响.中华消化杂志,2004:24(4):199-202.
[60]舒徐,吕农华,祝荫,等.幽门螺杆菌感染和P53蛋白的表达在胃粘膜病变中的关系.实用临床医学,2004:5(10):1-3.
[61]涂燕平,吕农华,谢勇,等.胃癌及癌前病变中P27kipl与转化生长因子β1之间关系的研究.胃肠病学,2002:7(增刊):A40.
[62]涂燕平,吕农华,谢勇,等.幽门螺杆菌感染与胃粘膜病变中P27kipl之间关系的研究.中华医学杂志,2002:82(增刊):123.
[63]熊碧芳,方向明,彭波,等.端粒酶RNA与胃粘膜HpcagA及增殖细胞核抗原表达的关系.临床内科杂志,2001:18(2):122-124.
[64]Kameshima H,Yagihashi A,Yajima T etal.Helicobacter pylori infection:augmentation of telomerase activity in cancer and noncancerous tissues.World J Surg,2000;24(10):1243 -1249.
[65]Farinati F,Cardin R,Oegan P,et al.0xidative DNA damage accumulation in gastric carcinogenesis.Gut,1998;42(3):351-356.
[66]房殿春,罗元辉,鲁荣,等.胃癌组织H-ras基因点突变与预后的关系[J].新消化病学杂志.1994:2(2):80-81.
[67]张红沽,赵志泉,王颖.胃粘膜组织中Bcl-2、Bax蛋白表达与胃癌的关系[J].河北医学,2001:7(10):865-873.
[68]Wang W,Luo HS,Yu BP.Telomerase and colorectal cancer[J].Shi jie Huaren Xiaohua Zazhi,2000;8:800.
[69]Burger AM,Mibby MC,Double JA.Telomerase activity in normal and malignant mammalian tissues:feasibility of telomerase as a target for cancer chemotherapy[J].Br J Cancer,1997:75:516.
[70]唐发清,蒋海鹰,段朝军,等.鼻咽上皮癌变过程中端粒酶活性和端粒酶RNA的表达[J].中华病理学杂志,2001:30:125.
[71]Kumakl F,Kawal T,Hirol S,et al.Telomerase activity and telomerase RNA component and hman telomerase reverse transcriptase in lung carci-nomas[J].Hum Pathol,2001;32:188.
[72]金梅,张维萍,罗元平,等.端粒酶基因在胃癌前病变的表达[J].中国实验诊断学.2005:9(2):219-220.
[73]沈汉澄.胃癌前病变WHO新标准与综合干预[J].浙江临床医学.2007:9(11):1441-1442.
[74]刘海峰,刘为纹,房殿春,等.幽门螺杆菌感染与胃癌前病变演化的关系[J].世界华人消化杂志,2002:20(8):912-915.
[75]Correa P,Fontham ET,Bravo JC etal.J Natl Cancer Inst,2000;92:1881-1882.
[76]Dixon MF.Gut,2001;49:2-4.
[77]靳桂艳.胶体果胶铋胶囊对胃癌前病变Bcl-2、P53基因蛋白影响的研究[J].中国医疗前沿.2007;1(2):52-54.
[78]胡品津,张汝逢.维酶素治疗慢性萎缩性胃炎疗效观察[J].新医学,1986:17(9):475-476.
[79]卢方,吴允华.联合叶酸和维霉素治疗慢性萎缩性胃炎疗效观察[J].浙江预防医学,2005:17(5):64-65.
[80]孟宪镛.胃癌癌前病变和胃癌相关疾病[J].交通医学,2006:20(4):364.
[81]李春启,刘为纹,房殿春,等.维甲酸对大鼠实验室性胃粘膜癌前病变的逆转、治疗作用[J].中华消化杂志,1994:14(6):319-322.
[82]李春启,刘为纹.丁酸钠治疗胃粘膜癌前病变的实验研究[J].中国肿瘤临床,1995;22(11):806-810.
[83]林瑶光.叶酸、维甲酸对胃癌前病变、胃癌逆转作用及抑癌机制[J].临床消化病杂志,2001:1:41.
[84]孙崇泉,冒云,陈明坤.叶酸对胃粘膜不典型增生的逆转作用[J].实用医技杂志,2003:10(4):335.
[85]Dannenberg AJ,Subbaramaiah K.Targeting cyclooxygenase-2 in human neoplasia:rationale and promise.Cancer cell,2003;4:431-436.
[86]Hu PJ,Yu J,Zeng ZR,et al.Chemoprevention of gastric cancer by celecoxib in rats.Gut,2004;53:195-200.
[87]Leung WK,Ng EK,Chan FK,et al.Effects of long-term rofecoxib on gastric intestional metaplasia:results of a randomized controlled trial,Clin Cancer Res,2006;12:4766-4722.
[88]Peraino C,Stafeldt EF,Cames BA,et al.Characterization of histochemically detectable altered hepatocycte foci and their relation to hepatic tumorigenesis in rats treated once with diethylnitrosaminer or benzo(a)pyrene with in one day after birth[J].Cancer Res,1984;44(8):3340-3347.
[89]Mitaka T,Tuskada H.Sexual difference in the histochemical characteristics of "altered cell foei" in liver of aged fischer 344 rats[J].Jpn J Cancer Res,1987;78(8):785-790.
[90]高进.肿瘤学基础与研究方法[M],北京:人民卫生出版社,1999;130.
[91]张新,范刚启.穴位注射对大鼠实验性胃癌前病变胃粘膜损伤的防治作用及对前列腺素E2、生长抑素的影响.浙江中医杂志,2006:41(12):698-699.
[92]王茵萍,查玮,孙茂峰,等.穴注黄芪、当归注射液对大鼠胃癌前病变胃粘膜上皮细胞影响的定量分析.天津中医,2002:19(5):58-60.
[93]孟振行,雷道年.亚硝基胍诱发大鼠胃腺癌发生和发展过程中病理学观察[J].临床与实验病理学杂志,1998:14(2):169-170.
[94]陈飞松,李春梅,任蜀兵,等.芪龙方防治大鼠胃癌癌前疾病的作用[J].中国中西医结合脾胃杂志,1999:7(2):68-71.
[95]Watenable T,Tada M,Nagai H,et al.Helicobacter priori infection induces gastric cancer in mongolian gerbils[J].Gastrenterology,1998;115(3):642-648.
[96]迟晶,傅宝玉.砂土鼠胃粘膜幽门螺杆菌长期感染的病理改变[J].世界华人消化杂志,2002:10(4):415.
[97]Drazek ES,Dubois A,Holmes RK.Characterization and presumptive identification of Helicobacter pylori isolates from rhesus monkeys[J].Clin Microbiol,1994;32(7):1799-1804.
[98]王晓梅,王瑞丽,刘俊田,等.金果胃康颗粒对胃癌前病变大鼠胃粘膜基因蛋白(P53、c-myc)表达的影响.山西中医,2003;19(3):49-50.
[99]Watanable H.Experimental induced intestinal eletaplasha in Wistar rats by x-ray radiation[J].Gastroenterology,1978;15:793.
[100]鲁香风,赵风志.中药治疗实验性慢性萎缩性胃炎的酶组化及电镜观察[J].中国中西医结合脾胃杂志,2000;8(5):257.
[101]王德俊,谢强敏.养胃冲剂对大鼠萎缩性胃粘膜的保护作用[J].解剖学研 究,2001;23(4):323.
[102]杨鸿,侯家玉.胆汁反流致慢性萎缩性胃炎的实验.北京中医药大学学报,2001;24(5):26.
[103]陆为民,单兆伟,吴静,等.大鼠慢性萎缩性胃炎癌前病变气虚血瘀证动物模型的研制.南京中医药大学学报(自然科学版),2000;5(16):156-158.
[104]李晓斌,夏天,张仲海,等.中药消萎灵对大鼠慢性萎缩性胃炎胃粘膜血流量和血浆胃动素的影响.第四军医大学学报,2002;23(9):772-775.
[105]谢晶日,王海强,王静滨.胃灵冲剂对慢性萎缩性胃炎大鼠胃粘膜影响的实验研究.中国中医药科技,2006;13(5):311-312.
[106]范英昌等.大鼠脾气虚型慢性萎缩性胃炎动物模型的实验研究.天津医药,1994;2,86.
[107]孙敬方.动物实验学[M],北京:人民卫生出版社,2001,第1版:462-463.
[108]Kleiner DE,Stetler-stevenson WG.Matrix metalloproteinases and metastasis,Cancer Chmemother Pharmacol,1999;(43suppl):S42.
[109]Pileher B,Dumin J,Sudbeck B,et al.The activity of collagenase-1 is required for keratinocyte migration on a type Ⅰ collagen matrix.J Cell BioL,1997;137(6):1445
[110]Deryugina EI,Bourdon MA,Jungwirth K,et al.Functional activation of integrin alpha V beta in tumor cells expressing membrane-type 1 matrix metalloproteinase.Int J Caneer,2000;86(1):15.
[111]Abdel-Ghany M,Cheng HC,Elble RC,et al.The breast cancer beta 4 integrin and endothelial human CLCA2 mediatding metastasis.J Biol Chem,2001:276(27):25438.
[112]Kabashima Y,Kakeji Y,et al.Clinicopathologieal features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis.Clln Cancer Res,2000;6(9):3581.
[113]Sun JM,Zheng HC,Yang XF,et al.Relationship between expression of matrix metalloproteinase-7 and clinicopathobiological behaviors of gastric cancer.Shijie Huaren Xiaohua Zhazi,2003;11:1310-1313.
[114]胡端敏,冯一中,王少峰.COX-2与MMP-7蛋自在胃癌组织中的表达及临床意义[J].苏州大学学报,2008:28(1):82-84,87.
[115]王绪霖,缴稳玲,吕宫舜,等.抑制幽门螺杆菌中药初步筛选杂志,1994;14(9):534.
[116]卢慧卿,杨京玉,丛英杰,等.珍珠粉、珍珠层粉药用价值的比较[J].天然产物研究与开发,1991:3(3):35-42.
[117]权伍荣.蒲公英提取物对小鼠胃粘膜损伤的恢复作用[J].第延边大学农学学 报,2008,30(4):276-279.
[118]赵浩如,李瑞,林以宁,等.白花蛇舌草不同提取工艺对抗肿瘤活性的影响[J].中国药科大学学报,2002,33(6):510.
[119]夏文娟,吴文涛,李淑君.白花蛇舌草联合化疗治疗晚期恶性肿瘤的疗效分析[J].四川省卫生管理干部学院学报,2001;6:93.[J].中国中西医结合
[120]吴厚铭,黄胜余,劳霞飞,等.白花蛇舌草免疫多糖结构的研究[J].有机化学,1992;12(4):428-431.
[121]于新,杜志坚,陈悦娇,等.白花蛇舌草提取物抗氧化作用的研究[J].食品与发酵工业,2002;28(3):10-13.
[122]Laddawan Boonyarathanakornkit,Chun-tao Che,Harry H,Fong S,et al.Constituents of Croton crassifolius Roots[J].Planta medica,1988;61.
[123]黄国栋,黄媛华,唐丽君.砂仁挥发油对胃溃疡粘膜PAF表达的影响[J].中药材,2008:31(11):1714-1716.
[124]刘友章.胃炎Ⅰ号对萎缩性胃炎病人胃粘膜修复作用之研究.中医杂志,1995:36(增刊):197.
[125]蓝惠玲,刘友章.胃炎Ⅰ号方治疗慢性萎缩性胃炎30例疗效观察.广州中医药大学学报,2005;5(3):170-178.